HYBRID KOL Event on Eneboparatide: A PTHR1 Agonist for Hypoparathyroidism
June 16, 2023 | 8:30 am CT (9:30 am ET)
Location: Sheraton Grand Chicago Riverwalk Chicago, IL
Advancing peptides for the treatment of rare endocrine and related diseases
We are a clinical stage, global company, building on our team’s established expertise to transform the lives of patients living with rare endocrine and related diseases.
PROGRAMS
Eneboparatide
Our lead clinical candidate is a potentially clinically superior therapeutic peptide in development for hypoparathyroidism.
Eneboparatide (red) bound to the PTH1 receptor. Adapted from Zhao et al. Science 364:138, 2019.
Image generated with the PyMOL Molecular Graphics System, Version 2.3.2 Schrödinger, LLC.
AZP-3813
AZP-3813 is a highly potent, peptide growth hormone (GH) receptor antagonist in development for acromegaly.
HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX. de Vos, A.M., Ultsch, M., Kossiakoff, A.A. (1992) Science 255: 306-312. Image created with Mol* (D. Sehnal, A.S. Rose, J. Kovca, S.K. Burley, S. Velankar (2018) Mol*: Towards a common library and tools for web molecular graphics MolVA/EuroVis Proceedings. doi:10.2312/molva.20181103). RCSB Protein Data Bank, PDB ID: 3HHR.
LEADERSHIP
Our management team has the collective and proven expertise necessary to advance its portfolio of innovative therapies in the clinic.
Press Releases & Recent News
Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
Download a PDF copy of this press release: EN FR Lyon, France, and Cambridge, MA, Nov. 16, 2023 — Amolyt
Read More →
Amolyt Pharma Announces Data on Prevalence of Bone Disease in Patients with Hypoparathyroidism and Favorable Bone Effects of Eneboparatide at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
Download a PDF copy of this press release: EN FR Patients from the Canadian National Hypoparathyroidism Registry were prospectively screened
Read More →